Duchenne muscular dystrophy has no cure but ongoing research and clinical trials finally offer hope for this devastating muscle wasting disease. MyoDys45-55 is designed to permanently fix the underlying cause of the disease for half of all Duchenne patients using this single platform. Future programs will develop similar strategies for more patients and other muscle diseases. MyoGene Bio’s goal is to have a significant impact on disease progression for devastating muscle disorders.